Description
Slifoxx (Zaleplon) 20 mg
Slifoxx 20 mg is a brand name for zaleplon, a short-acting sedative-hypnotic medicine used for short-term treatment of insomnia, mainly when the main problem is difficulty falling asleep. The supplied product description is consistent with the verified active ingredient and medicine class.
Active Ingredient and Medicine Class
The active ingredient is zaleplon. It belongs to the non-benzodiazepine hypnotic group, often described as a benzodiazepine receptor agonist or “Z-drug.” It acts on the central nervous system as a sedative-hypnotic.
Established Medical Uses
Official prescribing information identifies zaleplon for the short-term treatment of insomnia, especially trouble falling asleep. It is not presented as a treatment for all insomnia symptoms, and evidence suggests it is less useful for sleep maintenance than for sleep initiation.
How It Works
Zaleplon enhances the action of gamma-aminobutyric acid type A (GABA-A) receptors in the brain, producing a calming effect that helps reduce sleep latency. Its short half-life contributes to a brief hypnotic effect and fewer next-day residual effects than some longer-acting sleep medicines.
Important Safety Information
Zaleplon is contraindicated in people with known hypersensitivity to zaleplon or any formulation excipients. It carries important warnings about abnormal thinking or behaviour, amnesia, anxiety, depression, allergic reactions, and dependence or withdrawal-related effects. It can impair alertness and psychomotor performance, and the risk of next-day impairment is higher when combined with alcohol or other central nervous system depressants. The FDA label also notes reduced exposure with the strong enzyme inducer rifampin.
Possible Side Effects
Commonly reported adverse effects include headache, drowsiness, dizziness, memory problems, abnormal dreams, and taste disturbance. More serious reactions can include severe allergic responses, marked confusion, unusual behaviour, worsening depression, and rebound insomnia after stopping treatment, which was seen more often at higher doses in studies.
Scientific Evidence
Peer-reviewed reviews and clinical studies show that zaleplon is effective for sleep initiation and can reduce time to sleep onset. Evidence also indicates that its short duration makes it less effective for sleep maintenance, while next-day residual impairment is generally limited compared with longer-acting hypnotics. Some studies reported dose-related immediate psychomotor and memory effects at 20 mg.
Medical Information Notice
This page is an educational summary based on sources available at the time of review and does not replace the official patient leaflet or assessment by a qualified healthcare professional.
Medical Sources
- U.S. Food and Drug Administration (FDA) — Sonata (zaleplon) prescribing information. ([accessdata.fda.gov](https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/020859s015lbl.pdf))
- Marieke M. Ebbens, Joris C. Verster — Clinical evaluation of zaleplon in the treatment of insomnia. Neuropsychiatric Disease and Treatment, 2013. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/23616704/?utm_source=openai))
